Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Evaluating Vabicaserin in Subjects With Schizophrenia

ClinicalTrials.gov ID: NCT00563706

Public ClinicalTrials.gov record NCT00563706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia

Study identification

NCT ID
NCT00563706
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
199 participants

Conditions and interventions

Conditions

Interventions

  • vabicaserin Drug
  • risperidone Drug
  • placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2007
Primary completion
May 31, 2008
Completion
May 31, 2008
Last update posted
Mar 19, 2014

2007 – 2008

United States locations

U.S. sites
32
U.S. states
15
U.S. cities
30
Facility City State ZIP Site status
Pfizer Investigational Site Little Rock Arkansas 72201
Pfizer Investigational Site Cerritos California 90703
Pfizer Investigational Site Escondido California 92025
Pfizer Investigational Site Garden Grove California 92845
Pfizer Investigational Site Glendale California 91206
Pfizer Investigational Site San Diego California 92103
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site Torrance California 90502
Pfizer Investigational Site Washington D.C. District of Columbia 20016
Pfizer Investigational Site Aventura Florida 33180
Pfizer Investigational Site Hollywood Florida 33021
Pfizer Investigational Site Kissimmee Florida 34741
Pfizer Investigational Site Hoffman Estates Illinois 60169
Pfizer Investigational Site Indianapolis Indiana 46222
Pfizer Investigational Site Lake Charles Louisiana 70601
Pfizer Investigational Site Baltimore Maryland 21202
Pfizer Investigational Site Rockville Maryland 20850
Pfizer Investigational Site Hamilton New Jersey 08619
Pfizer Investigational Site Willingboro New Jersey 08046
Pfizer Investigational Site Cedarhurst New York 11516
Pfizer Investigational Site Holliswood New York 11423
Pfizer Investigational Site New York New York 10032
Pfizer Investigational Site Butner North Carolina 27509
Pfizer Investigational Site Oklahoma City Oklahoma 73103
Pfizer Investigational Site Philadelphia Pennsylvania 19131
Pfizer Investigational Site Austin Texas 78754
Pfizer Investigational Site Austin Texas 78756
Pfizer Investigational Site Bellaire Texas 77008
Pfizer Investigational Site DeSoto Texas 75115
Pfizer Investigational Site Houston Texas 77008
Pfizer Investigational Site Arlington Virginia 22201
Pfizer Investigational Site Portsmouth Virginia 23707

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00563706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 19, 2014 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00563706 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →